期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌免疫治疗研究进展 被引量：1

Research Progress on Immunotherapy of Breast Cancer
下载PDF
导出
摘要 肿瘤的免疫治疗是指通过给予某些生物物质或刺激宿主产生免疫防御应答以取得抗肿瘤效应的治疗方法的总称。随着免疫学和分子生物学的研究,乳腺癌的免疫治疗取得了一定的进步。本文对乳腺癌的免疫治疗研究进展作一综述。 Tumor immunotherapy is to obtain anti-tumor effect of treatment by giving certain biological substances or stimulating the host to produce natural immune defense mechanisms. With the development of immunology and molecular biological techniques, immunotherapy of breast cancer has also made some progress. So the aim of this paper is to summarize the research progress on immunotherapy of breast cancer.
作者 尹令丝 黄俊琼
机构地区 遵义医学院附属医院检验科
出处 《临床医学工程》 2013年第2期259-260,共2页 Clinical Medicine & Engineering
关键词 乳腺癌 免疫治疗 Breast cancer Immunotherapy
分类号 R737.9 [医药卫生—肿瘤] R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献48

  • 1胡小倩,吴立萍,陈晓密.细胞因子作为DNA疫苗基因佐剂的研究进展和探索[J].中华临床医师杂志（电子版）,2011,5(14):4183-4185. 被引量：2
  • 2Chang JC,Hilsenbeck SG,Fuqua SA.Genomic approaches in the management and treatment of breast cancer.Br J Cancer,2005,92:618-624.
  • 3Taylor PJ,Burchell JM,Plunkett T,et al.MUC1 and the immunobiology of cancer.J Mammary Gland Biol Neoplasia,2002,7:209-221.
  • 4Soares MM,Mehta V,Finn OJ.Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.J Immunol,2001,166:6555-6563.
  • 5Chen D,Xia J,Tanaka Y,et al.Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.Immunology,2003,109:300-307.
  • 6Snyder LA,Goletz TJ,Gunn GR,et al.A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.Vaccine,2006,24:3340-3352.
  • 7Schroeder JA,Masri AA,Adriance MC,et al.MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation.Oncogene,2004,23:5739-5747.
  • 8Dranof G.GM-CSF-secreting melanoma vaccines.Oncogene,2003,22:3188-3192.
  • 9Mukherjee P,Ginardi AR,Madsen CS,et al.Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.J Immunol,2000,165:3451-3460.
  • 10Chung MA,Luo Y,O'Donnell M,et al.Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine.Cancer Res,2003,63:1280-1287.

共引文献4

同被引文献37

  • 1Dillman RO,Cancer immunotherapy[J].Cancer Biother Radiopharm,2011,26(1);1-64.
  • 2Page DB,Naidoo J,McArthur HL.Emerging immunotherapy strategies in breast cancer[J].Immunotherapy,2014,6(2):195-209.
  • 3Bahl S,Roses RE,Sharma A,et al.Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/ neu-pulsed dendritic cell vaccines[J].Am J Surg,2009,198(4):488-494.
  • 4Xie Y,Chen Y,Ahmed KA,et al.Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell- induced immunity against Tgl-I breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses[J].Cancer Gene Ther,2013,20(10):590-598.
  • 5Zheng X,Koropatnick J,Chen D,et al.Silencing IDO in dendritic cells:a novel approach to enhance cancer immunotherapy in a murine breast cancer model[J].Int J Cancer,2013,132(4):967-977.
  • 6Ge Y,Xi H,Ju S,et al.Blockade of PD-I/PD-Ll immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice[J].Cancer Lett,2013,336(2);253-259.
  • 7Baek S,Kim CS,Kim SB,et al.Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2:results from a phase I / II trial[J].J Transl Med,2011,9:178.
  • 8Hafid SR,Hadhakrishnan AK,Nesaretnam K.Tocotrienols are good adjuvants for developing cancer vaccines[J].BMC Cancer,2010,10:5.
  • 9Hamilton E,Blackwell K,Hobeika AC,et al.Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition[J].J Transl Med,2012,10:28.
  • 10Gritzapis AD,Fridman A,Perez SA,et al.HER-2/neu (657-665)represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties[J].Vaccine,2009,28(1):162-170.

引证文献1

二级引证文献6

临床医学工程
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部